Ligand Pharmaceuticals Incorporated — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are with FY2020 unless stated otherwise. Ligand is a biopharmaceutical technology and licensing company whose revenue is primarily royalties, Captisol material sales, and contract revenue. Its partners fund development and commercialization for more than 400 partnered programs.
Financial results and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Total revenue | $277.1 million | $186.4 million | +49% |
| Royalties | $48.9 million | $33.8 million | +45% |
| Captisol sales | $164.3 million | $110.0 million | +49% |
| Contract revenue | $64.0 million | $42.7 million | +50% |
| Income from operations | $78.9 million | $25.8 million | — |
| Net income (loss) | $57.1 million | $(3.0) million | — |
| Operating cash flow | $78.8 million | $54.6 million | — |
Calculated from reported figures, operating margin was approximately 28.5% and net margin approximately 20.6%. FY2021 operating income included $37.6 million of other operating income from writing the Pfenex contingent value right liability down to zero after its milestone deadline expired. The filing does not present adjusted margins excluding this item.
Revenue growth reflected higher Captisol shipments to Gilead for Veklury (remdesivir), increased royalties from Kyprolis and Evomela, royalties from additional partnered products, and higher contract and milestone revenue. Kyprolis royalties were $27.5 million and Evomela royalties were $10.1 million. Captisol cost rose to $62.2 million from $30.4 million. R&D expense increased 16% to $69.0 million; G&A declined 11% to $57.5 million.
At year-end, cash and cash equivalents were $19.5 million and short-term investments were $321.6 million, totaling approximately $341.1 million. Current assets were $464.8 million and current liabilities $41.7 million. Total assets were $1.298 billion, total liabilities $476.4 million, and stockholders’ equity $821.2 million. Short-term investments included $30.9 million of Viking shares. The company reported $343.3 million principal outstanding on its 0.75% convertible notes due 2023 ($320.7 million net carrying amount). It repurchased $152.0 million principal during 2021 for $156.0 million cash; in February 2022, it repurchased a further $125.5 million principal for $123.9 million cash.
Investing activities provided $30.5 million, principally reflecting proceeds from sales and maturities of investments; financing activities used $137.8 million, including debt repayment. The company reported no 2021 common-stock repurchases and had $248.8 million remaining under its $500 million authorization.
Material developments, outlook and risks
- OmniAb separation: Ligand expected to pursue a direct spin-off of 100% of OmniAb to shareholders, with Ligand contributing $70 million of capital. At filing, completion was expected in the first half of 2022, subject to board approval and other conditions; no assurance was given that it would occur or deliver expected benefits.
- Partner pipeline: OmniAb-derived sugemalimab received approval in China, and Janssen submitted a U.S. BLA for teclistamab. Merck’s VAXNEUVANCE received adult approvals in the U.S. and Europe. These developments may support future royalties and milestones, but timing and amounts depend on partner decisions, regulatory outcomes, and product sales.
- No company-level financial guidance: The filing does not provide a clear numerical revenue, earnings, or cash-flow forecast. Management noted that R&D project costs and completion timelines are difficult to estimate.
- Concentration and supply: Two partners each accounted for at least 10% of revenue (41% and 14%); the concentration table does not identify them. Captisol revenue depended significantly on Veklury demand, and Captisol is sourced primarily from a single supplier, Hovione. The filing flags potential demand changes, supply interruption, customer credit risk, and partner termination as risks.
- Competition and patent exposure: Generic entry could affect partnered-product revenues; the filing cites a Teva settlement permitting U.S. generic Evomela sales from June 1, 2026 or earlier under certain circumstances, and reported possible Kyprolis generic entry in 2027 or sooner. Captisol and royalty receipts may also be affected by patent challenges and expirations.
- Other notable matters: Baxter disputed Captisol-related Nexterone royalties; arbitration was scheduled for May 2022. The company said it did not believe pending claims were likely to have a material adverse effect, but litigation outcomes are uncertain. COVID-19 had not materially disrupted Ligand’s operations to date, though partner and trial disruptions remained possible.
Ernst & Young issued an unqualified opinion on the financial statements and internal controls; management and the auditor concluded internal control over financial reporting was effective at December 31, 2021.
Important facts for investors to verify
- Progress, final terms, funding, and completion of the OmniAb separation.
- How much FY2021 Captisol revenue depended on Veklury and whether future demand sustains the unusually high sales level.
- Identity and ongoing exposure to the two unnamed partners representing 41% and 14% of revenue, and whether customer receivables are collected.
- Remaining 2023 convertible-note principal after the February 2022 repurchase and any further repurchases or potential dilution.
- Partner pipeline milestones, approvals, launches, and commercial sales supporting future royalties, especially sparsentan, teclistamab, and other late-stage programs.
- Outcome of the Baxter arbitration and the timing and impact of generic competition for Evomela and Kyprolis.